Valsagel, a temporary birth control injection for men, is set to hit the market in 2018, Cosmopolitan reports. Developed by the Parsemus Foundation, Valsagel is a horomone-free gel injected into the testes to stop sperm from being transported through a tube called the vas deferens. A new study suggests that the gel is both effective and reversible; when 12 rabbits were injected with Valsagel, 11 were found to have no sperm in their semen for one year after the injection. When scientists flushed the gel out with a second injection, sperm flow returned.
But the drug’s development is still in the preliminary stages. Valsagel has yet to undergo human trials, and certain details about the contraceptive are still a bit … hazy. “It seems to be pretty durable; we expect it to last for years,” Elaine Lissner, executive director of the Parsemus Foundation, told Cosmopolitan. “We just don’t know how many yet.” Moving forward, Parsemus will train physicians to administer the injection, and the organization plans to launch human trials later this year. To offset the steep costs of developing Valsagel, Parsemus is also seeking to bring new investors on to the project. “There are so many men who want this so badly,” Lissner said. “The support is going to be there.”
Read the full story at Cosmopolitan.com.